Capital Increase Take-off for Natraceutical: Euro20 Million


Madrid - The Board of Spanish specialist for food, Natraceutical, approved in its April meeting the issue of 38,521,165 new shares, for a nominal amount of Euro3,852,116.5, allowing it to raise Euro20,031,005.80. The new shares will have the same rights as all bonds currently in circulation, taking effect from January 1, 2004, and with an issue price of Euro0.52.
Upon the approval of the prospectus by the Comisión Nacional de Mercado de Valores CNMV (National Stock Exchange Comission) , a 10-day period will be established to enable Natraceutical's shareholders to subscribe 5 new shares for every 19 old shares in their possession the day before this preferential subscription period commences and in which the rights, valued according to closing on April 22 at Euro0.075, will also be listed.
The Euro20 million , which Natraceutical will raise, will enable it to strengthen its resources and deal with projects which are included in the prospectus of its floating on the stock market, in addition to other product or business lines in which it's working.
Natraceutical currently markets 22 functional ingredients for the food industry. During 2003 and 2004 it has applied for five patents for functional ingredients and active principles, all derived from raw, natural materials, especially from the Mediterranean area. The company produces active compunds and biotechnological ingredients and develops functional foods as well. It also takes part in Biópolis, a biotechnological company directed at custom-made R&D activities for the food and pharmaceutical sectors, which was launched in April 2003 with the Consejo Superior de Investigaciones Científicas (Board of Scientific Research-CSIC), CAPSA and the Capital-Risk entity, TALDE. In 2003, Natraceutical achieved net profits of Euro2 million, thus multiplying six-fold its previous year's profits.
The world market for functional ingredients and nutraceuticals, whose main markets are the United States and Japan, rose to more than $34 billion in 2002, reflecting a growth of 9.2% compared with the previous year.



Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...



Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...



Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...



Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain


Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...



Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...



Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...



Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...



Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2015 BIOCOM



All videos

Product of the week



All Events

Stock list

All quotes


  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%


  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%


  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%


  • BIOTEST (D)27.24 EUR-60.8%
  • TRANSGENE (F)2.80 EUR-23.9%


  • ADOCIA (F)88.74 EUR531.6%
  • DBV TECHNOLOGIES (F)81.03 EUR325.4%
  • FORMYCON (D)28.70 EUR321.4%


  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEOVACS (F)1.01 EUR-70.6%

No liability assumed, Date: 04.08.2015

Current issue

All issues